Pain Therapeutics, Inc. (NASDAQ:PTIE) – Equities research analysts at Gabelli upped their FY2017 earnings per share estimates for Pain Therapeutics in a report issued on Wednesday. Gabelli analyst K. Kedra now forecasts that the biopharmaceutical company will earn ($1.90) per share for the year, up from their prior estimate of ($2.20). Gabelli also issued estimates for Pain Therapeutics’ FY2018 earnings at ($2.50) EPS, FY2019 earnings at ($5.00) EPS, FY2020 earnings at ($4.70) EPS and FY2021 earnings at ($3.50) EPS.
Several other equities research analysts also recently weighed in on PTIE. Zacks Investment Research downgraded shares of Pain Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 19th. ValuEngine downgraded shares of Pain Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st.
Pain Therapeutics (NASDAQ:PTIE) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.40) earnings per share for the quarter.
A hedge fund recently bought a new stake in Pain Therapeutics stock. Dimensional Fund Advisors LP bought a new position in Pain Therapeutics, Inc. (NASDAQ:PTIE) in the second quarter, according to the company in its most recent disclosure with the SEC. The fund bought 59,989 shares of the biopharmaceutical company’s stock, valued at approximately $247,000. Dimensional Fund Advisors LP owned 0.91% of Pain Therapeutics at the end of the most recent quarter. 35.99% of the stock is owned by institutional investors.
About Pain Therapeutics
Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.
Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.